Novel Polypeptides and Use Thereof

Russell Collighan (Inventor), Martin Griffin (Inventor), Kamila Pytel (Inventor), Zhuo Wang (Inventor)

Research output: Patent

Abstract

A polypeptide capable of modulating tissue transglutaminase-induced cell behaviour comprises either (a) a heparin-binding site of a tissue transglutaminase (TG2), or a functional fragment, variant, fusion or derivative thereof, or an antibody capable of binding to the heparin-binding site of TG2, or a antigen-binding fragment or derivative thereof. Peptides comprising the heparin-binding site of TG2 bind to heparin-sulphate proteoglycans such as syndecan-4, and may be used for wound healing, and for use in medical implants. Antibodies binding to the heparin-binding site of TG2 may be useful for inhibiting angiogenesis, and treating fibrosis (including cystic fibrosis), scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, cancer, AIDS, psoriasis, chronic inflammatory diseases, coeliac disease and organ transplant rejection.
LanguageEnglish
Patent numberGB 1107147.9
IPCA61K38/04
Publication statusPublished - 28 Apr 2011

Fingerprint

Heparin
Binding Sites
Peptides
Syndecan-4
Antibodies
Graft Rejection
Celiac Disease
Psoriasis
Cystic Fibrosis
Neurodegenerative Diseases
Wound Healing
Autoimmune Diseases
Cicatrix
Acquired Immunodeficiency Syndrome
Thrombosis
Fibrosis
Chronic Disease
Transplants
Antigens
Neoplasms

Cite this

Collighan, R., Griffin, M., Pytel, K., & Wang, Z. (2011). IPC No. A61K38/04. Novel Polypeptides and Use Thereof. (Patent No. GB 1107147.9).
Collighan, Russell (Inventor) ; Griffin, Martin (Inventor) ; Pytel, Kamila (Inventor) ; Wang, Zhuo (Inventor). / Novel Polypeptides and Use Thereof. IPC No.: A61K38/04. Patent No.: GB 1107147.9.
@misc{d917573298404d278e6414e4abd56178,
title = "Novel Polypeptides and Use Thereof",
abstract = "A polypeptide capable of modulating tissue transglutaminase-induced cell behaviour comprises either (a) a heparin-binding site of a tissue transglutaminase (TG2), or a functional fragment, variant, fusion or derivative thereof, or an antibody capable of binding to the heparin-binding site of TG2, or a antigen-binding fragment or derivative thereof. Peptides comprising the heparin-binding site of TG2 bind to heparin-sulphate proteoglycans such as syndecan-4, and may be used for wound healing, and for use in medical implants. Antibodies binding to the heparin-binding site of TG2 may be useful for inhibiting angiogenesis, and treating fibrosis (including cystic fibrosis), scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, cancer, AIDS, psoriasis, chronic inflammatory diseases, coeliac disease and organ transplant rejection.",
author = "Russell Collighan and Martin Griffin and Kamila Pytel and Zhuo Wang",
year = "2011",
month = "4",
day = "28",
language = "English",
type = "Patent",
note = "GB 1107147.9; A61K38/04",

}

Collighan, R, Griffin, M, Pytel, K & Wang, Z 2011, Novel Polypeptides and Use Thereof, Patent No. GB 1107147.9, IPC No. A61K38/04.

Novel Polypeptides and Use Thereof. / Collighan, Russell (Inventor); Griffin, Martin (Inventor); Pytel, Kamila (Inventor); Wang, Zhuo (Inventor).

IPC No.: A61K38/04. Patent No.: GB 1107147.9.

Research output: Patent

TY - PAT

T1 - Novel Polypeptides and Use Thereof

AU - Collighan, Russell

AU - Griffin, Martin

AU - Pytel, Kamila

AU - Wang, Zhuo

PY - 2011/4/28

Y1 - 2011/4/28

N2 - A polypeptide capable of modulating tissue transglutaminase-induced cell behaviour comprises either (a) a heparin-binding site of a tissue transglutaminase (TG2), or a functional fragment, variant, fusion or derivative thereof, or an antibody capable of binding to the heparin-binding site of TG2, or a antigen-binding fragment or derivative thereof. Peptides comprising the heparin-binding site of TG2 bind to heparin-sulphate proteoglycans such as syndecan-4, and may be used for wound healing, and for use in medical implants. Antibodies binding to the heparin-binding site of TG2 may be useful for inhibiting angiogenesis, and treating fibrosis (including cystic fibrosis), scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, cancer, AIDS, psoriasis, chronic inflammatory diseases, coeliac disease and organ transplant rejection.

AB - A polypeptide capable of modulating tissue transglutaminase-induced cell behaviour comprises either (a) a heparin-binding site of a tissue transglutaminase (TG2), or a functional fragment, variant, fusion or derivative thereof, or an antibody capable of binding to the heparin-binding site of TG2, or a antigen-binding fragment or derivative thereof. Peptides comprising the heparin-binding site of TG2 bind to heparin-sulphate proteoglycans such as syndecan-4, and may be used for wound healing, and for use in medical implants. Antibodies binding to the heparin-binding site of TG2 may be useful for inhibiting angiogenesis, and treating fibrosis (including cystic fibrosis), scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, cancer, AIDS, psoriasis, chronic inflammatory diseases, coeliac disease and organ transplant rejection.

M3 - Patent

M1 - GB 1107147.9

ER -

Collighan R, Griffin M, Pytel K, Wang Z, inventors. Novel Polypeptides and Use Thereof. A61K38/04. 2011 Apr 28.